ELAN
NYSEElanco Animal Health Incorporated
News · 26 weeks111+27%
2026-03-012026-08-23
Mix4290d
- Insider28(67%)
- Other9(21%)
- SEC Filings3(7%)
- Earnings2(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Officer Modi Rajeev A.4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERSEC Form 4 filed by EVP and CFO Vanhimbergen Robert M4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Kurzius Lawrence Erik bought $935,920 worth of shares (40,000 units at $23.40), increasing direct ownership by 27% to 188,647 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERGC AND CORP SEC O'Neill Shiv bought $94,273 worth of shares (3,998 units at $23.58), increasing direct ownership by 5% to 87,832 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Harrington Michael J bought $109,100 worth of shares (5,000 units at $21.82), increasing direct ownership by 4% to 131,451 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDEREVP and CFO Vanhimbergen Robert M bought $96,926 worth of shares (4,200 units at $23.08), increasing direct ownership by 3% to 137,516 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERSEC Form 4 filed by Officer Modi Rajeev A.4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERDirector Herendeen Paul bought $236,850 worth of shares (10,000 units at $23.68), increasing direct ownership by 10% to 111,687 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- PRElanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife SpeciesVigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical expertsEmergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm infestations.Elanco also offers producers Negasunt® Powder (coumaphos, propoxur, and sulfanilamide topical powder) and Tanidil®, which received emergency authorizations earlier this year, as well as EPA-registered Catron™ IV.Elanco's technical experts emphasize "eyes on livestock" and early intervention are the most effective ways to minimize animal injury and prevent the parasite's spread.INDIANAPOLIS, Aug. 7, 2
- SECSEC Form 10-Q filed by Elanco Animal Health Incorporated10-Q - Elanco Animal Health Inc (0001739104) (Filer)
- SECElanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Elanco Animal Health Inc (0001739104) (Filer)
- PRElanco Animal Health Reports Second Quarter 2026 ResultsRaising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio TargetSecond Quarter 2026 Financial Results: Revenue of $1,368 million, an increase of 10% year-over-year; 8% organic constant currency growth Reported Net Income of $54 million, Adjusted Net Income of $174 million Adjusted EBITDA of $288 million; Adjusted EBITDA Margin of 21.2% Reported EPS of $0.11, Adjusted EPS of $0.34 Net leverage ratio of 3.1x Adjusted EBITDAFull Year 2026 Guidance:Raising innovation revenue target to $1.25 billionRaising revenue guidance to $5.09 billion to $5.14 billion, or 6% to 7% organic constant currency growthRaising Adjusted EBITDA to $1.01 billion to $1.035 billion, a year-o
- PRElanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing NeedsReport highlights Elanco's impact through innovation, expanded access to animal care, a stronger and more sustainable food system and investment in people and communitiesINDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2025 Impact Report, "Leading with Purpose," highlighting how the company brings together purpose, innovation and business strategy to help address some of society's most pressing challenges. The report details Elanco's progress across four interconnected areas: going beyond for animals, customers, society and its people. Together, these priorities demons
- INSIDERSEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERSEC Form 4 filed by Officer Modi Rajeev A.4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERSEC Form 4 filed by EVP and CFO Vanhimbergen Robert M4 - Elanco Animal Health Inc (0001739104) (Issuer)
- PRCredelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro:Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours of treatment.iKills the lone star tick (Amblyomma americanum) within 12 hours of infestation; achieving the fastest3 initial speed of tick kill compared to the competition.iiAchieves a rapid speed of kill4 on Day 0 and on Day 28, with no statistically significant drop-off in performance at the end of the dosing period.i,iiOutlasts competitors whose speed of kill2,4 performance declined at the end of the month.i,iiINDIANAPOLIS, July 22, 2026 /PRNewswire/ -- When it comes to killing ticks, veterin
- INSIDERSEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERSEC Form 4 filed by EVP and CFO Vanhimbergen Robert M4 - Elanco Animal Health Inc (0001739104) (Issuer)
- INSIDERSEC Form 4 filed by Officer Modi Rajeev A.4 - Elanco Animal Health Inc (0001739104) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Elanco Animal Health IncorporatedSCHEDULE 13G - Elanco Animal Health Inc (0001739104) (Subject)
- INSIDEREVP and CFO Vanhimbergen Robert M covered exercise/tax liability with 15,336 shares, decreasing direct ownership by 10% to 133,316 units (SEC Form 4)4 - Elanco Animal Health Inc (0001739104) (Issuer)
- PRElanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results AnnouncementINDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/news-events/events-presentation. A replay will also be available on the website shor
ELAN FAQ
7 questionsWhat does Elanco Animal Health Incorporated do?
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and...Where does ELAN stock trade?
Elanco Animal Health Incorporated (ELAN) is listed on NYSE.What sector and industry is ELAN in?
Elanco Animal Health Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Elanco Animal Health Incorporated go public?
Elanco Animal Health Incorporated (ELAN) completed its IPO in 2018.What are analysts saying about ELAN?
Elanco Animal Health Incorporated has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $3000.00 price target on 2026-04-15. Recent price targets range from $1800.00 to $3000.00.What companies are similar to ELAN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ELAN side-by-side with any of them on Quantisnow.How can I track ELAN on Quantisnow?
Quantisnow aggregates Elanco Animal Health Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELAN to receive live email and push alerts on every new disclosure.